Mepolizumab improved airway hyperresponsiveness in a patient with allergic bronchopulmonary aspergillosis.
Asian Pac J Allergy Immunol
; 2021 11 07.
Article
em En
| MEDLINE
| ID: mdl-34742225
ABSTRACT
BACKGROUND:
Allergic bronchopulmonary aspergillosis (ABPA) is a severe type of asthma characterized by hypersensitivity to Aspergillus fumigatus and lung infiltration with eosinophilia. The central pathogenesis of asthma is airway hyperresponsiveness (AHR), with eosinophils playing a critical role. Anti-interleukin (IL)-5 antibody therapy has been recently introduced to treat severe asthma, which reportedly inactivates and reduces eosinophil count. A recent case series highlighted the improvement in asthmatic symptoms associated with ABPA, but previous reports failed to demonstrate any improvement in AHR.OBJECTIVE:
Herein, we aimed to elucidate the efficacy of mepolizumab in a patient with ABPA who showed improvement in AHR.METHODS:
Case report.RESULTS:
A 63-year-old Asian woman with ABPA showed improvement in asthmatic symptoms and AHR following mepolizumab therapy.CONCLUSIONS:
Our results suggest that IL-5 may serve in the pathogenesis of ABPA.
Texto completo:
1
Base de dados:
MEDLINE
Idioma:
En
Ano de publicação:
2021
Tipo de documento:
Article